Regulated cell death (RCD), also well-known as programmed cell death (PCD), refers to the
form of cell death that can be regulated by a variety of biomacromolecules, which is …

TP53 is a critical tumor-suppressor gene that is mutated in more than half of all human
cancers. Mutations in TP53 not only impair its antitumor activity, but also confer mutant p53 …

The efficacy and synthetic versatility of asymmetric organocatalysis have contributed
enormously to the field of organic synthesis since the early 2000s. As asymmetric …

Dysfunction of the TP53 (p53) gene occurs in most if not all human malignancies. Two
principal mechanisms are responsible for this dysfunction; mutation and downregulation of …

The cytotoxic anti-cancer drugs cisplatin, paclitaxel, doxorubicin, 5-fluorouracil (5-FU), as
well as targeted drugs including imatinib, erlotinib, and nivolumab, play key roles in clinical …

Disruption of the MDM2-p53 protein-protein interaction by small-molecule inhibitors has
been highly pursued by many academic laboratories and pharmaceutical companies as a …

Despite being the subject of extensive research and clinical trials, neuroblastoma remains a
major therapeutic challenge in pediatric oncology. The p53 protein is a central safeguard …

Abstract Mouse double minute 2 (MDM2) is an E3 ubiquitin ligase which effectively
degrades tumor suppressor p53. In the past two decades, many MDM2 inhibitors that disrupt …

The p53 tumor suppressor protein and its major negative regulators MDM2 and MDMX
oncoproteins form the MDM2/MDMX-p53 circuitry, which plays critical roles in regulating …

Epigenetic enzymes histone deacetylases (HDACs) are clinically validated anticancer drug
targets which have been studied intensively in the past few decades. Although several drugs …